30 completed, 11 unknown, 8 recruiting, 8 terminated. 64 Phase 1, 21 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 64 | Completed 30, Unknown 11, Recruiting 8, Terminated 8, Withdrawn 4, Active not recruiting 3 |
| Phase 2 | 21 | Completed 8, Unknown 6, Recruiting 5, Withdrawn 2 |
Follow Acute Lymphocytic Leukemia: new trials by email Literature Review of Acute Lymphocytic Leukemia trials Research Report on Acute Lymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL CAR19TIF cells, Fludarabine, Cyclophosphamide - Acute Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Chinese PLA General Hospital | 30 | 2025-06-20 | 2025-06-25 |
| TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL TCR reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T cell, Fludarabine, Cyclophosphamide - Acute Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Chinese PLA General Hospital | 30 | 2025-02-15 | 2026-05-08 |
| A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies Fludarabine + Total Marrow Irradiation - Acute Myeloid Leukemia, Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | Naoyuki G. Saito, M.D., Ph.D. | 2023-10-01 | 2023-12-11 | |
| Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors KT-253 - Myeloid Malignancies, Acute Lymphocytic Leukemia | Phase 1 | Completed | Kymera Therapeutics, Inc. | 52 | 2023-05-15 | 2025-01-27 |
| Pilot Imaging Study of Leukemia FLT - Acute Lymphocytic Leukemia, Acute Myeloid Leukemia | Phase 1 | Recruiting | University of Oklahoma | 60 | 2023-01-19 | 2026-04-23 |
| CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies CD19/CD22-CAR-transduced T cells, cyclophosphamide, fludarabine - B-NHL, B-Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 130 | 2022-12-28 | 2026-10-26 |
| Cryopreserved MMUD BM With PTCy for Hematologic Malignancies Cyclophosphamide, Fludarabine, Total Body Irradiation - Acute Leukemia, Myelodysplastic Syndromes | Phase 1 | Withdrawn | Ossium Health, Inc. | 2022-09-01 | 2026-02-24 | |
| Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies CAR-NK-CD19 Cells - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 | Withdrawn | Beijing Boren Hospital | 2022-05-10 | 2026-10-15 | |
| Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. LP-118 - Non Hodgkin Lymphoma, Richter Transformation | Phase 1 | Recruiting | Newave Pharmaceutical Inc | 100 | 2022-05-08 | 2026-05-05 |
| CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia CD19-targeted Chimeric Antigen Receptor (CAR) T Cells - Acute Lymphocytic Leukemia | Phase 1 | Unknown | Shanghai Ming Ju Biotechnology Co., Ltd. | 33 | 2022-04-28 | 2023-02-14 |
| A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia LCAR-AIO Cells - Acute Lymphocytic Leukemia | Phase 1 | Terminated | Institute of Hematology & Blood Diseases Hospital, China | 10 | 2022-03-14 | 2025-06-03 |
| A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia Revumenib, Chemotherapy Regimen 1, Chemotherapy Regimen 2 - Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia | Phase 1 | Completed | Syndax Pharmaceuticals | 30 | 2022-03-09 | 2024-08-13 |
| Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy Duvelisib, CAR T-cells - Non-Hodgkin Lymphoma, Acute Lymphocytic Leukemia | Phase 1 | Active not recruiting | Washington University School of Medicine | 42 | 2022-02-28 | 2026-09-24 |
| Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 27 | 2021-04-10 | 2021-04-08 |
| Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors Ponatinib - Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | Incyte Biosciences International Sàrl | 70 | 2020-01-29 | 2026-10-09 |
| Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation Stem cell transplantation, Itacitinib, Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 1 | Completed | Washington University School of Medicine | 55 | 2019-09-04 | 2025-04-06 |
| CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia CD7 CAR-T cells infusion - T-lymphoblastic Lymphoma, NK/T Cell Lymphoma | Phase 1 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2019-08-25 | 2020-09-28 |
| Senl_1904A and Senl_1904B Chimeric Antigen Receptor （CAR） T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia Autologous CD19-targeting CAR T cells - Acute Lymphocytic Leukemia | Phase 1 | Unknown | Hebei Senlang Biotechnology Inc., Ltd. | 20 | 2019-01-02 | 2021-01-20 |
| A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 CPX-351 - Hematologic Malignancy, Acute Myeloid Leukemia | Phase 1 | Completed | Jazz Pharmaceuticals | 21 | 2018-11-20 | 2021-07-22 |
| IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT Fludarabine, Total Marrow Irradiation (TMI) - Acute Myeloid Leukemia, Chronic Myeloid Leukemia | Phase 1 | Terminated | Naoyuki G. Saito, M.D., Ph.D. | 6 | 2018-08-29 | 2022-03-09 |
Showing 20 of 64. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (64) · Leukemia, Myeloid, Acute (30) · Leukemia, Lymphocytic, Chronic, B-Cell (21) · Lymphoma, Non-Hodgkin (15) · Myelodysplastic Syndromes (15) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (12) · Lymphoma (12) · Leukemia (11) · Recurrence (10) · Hematologic Neoplasms (7) · Burkitt Lymphoma (6) · Hodgkin Disease (6) · Lymphoma, Follicular (6) · Multiple Myeloma (6) · Lymphoma, Mantle-Cell (5)
Hematologic Diseases (64) · Hemic and Lymphatic Diseases (64) · Immune System Diseases (64) · Immunoproliferative Disorders (64) · Lymphatic Diseases (64) · Lymphoproliferative Disorders (64) · Neoplasms by Histologic Type (64) · Leukemia, Lymphoid (63) · Neoplasms (63) · Leukemia (53) · Pathologic Processes (34) · Pathological Conditions, Signs and Symptoms (34) · Disease Attributes (32) · Leukemia, Myeloid (31) · Chronic Disease (29)
Cyclophosphamide (13) · fludarabine (13) · fludarabine phosphate (8) · Antigens, CD19 (3) · Busulfan (3) · Filgrastim (3) · Granulocyte Colony-Stimulating Factor (3) · Immunotherapy, Adoptive (3) · Mesna (3) · Sensitivity and Specificity (3) · Stem Cell Transplantation (3) · Vincristine (3) · Whole-Body Irradiation (3) · Antilymphocyte Serum (2) · Clofarabine (2)
National Cancer Institute (NCI) (4) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (4) · M.D. Anderson Cancer Center (3) · Traws Pharma, Inc. (3) · Washington University School of Medicine (3) · Baylor College of Medicine (2) · Callisto Pharmaceuticals (2) · Chinese PLA General Hospital (2) · Masonic Cancer Center, University of Minnesota (2) · Naoyuki G. Saito, M.D., Ph.D. (2) · University Health Network, Toronto (2) · University of Pennsylvania (2) · Assistance Publique - Hôpitaux de Paris (1) · AstraZeneca (1) · Beijing Boren Hospital (1)
United States (44) · China (14) · Canada (6) · France (2) · Germany (2) · Netherlands (2) · United Kingdom (2) · Belgium (1) · Israel (1) · Italy (1) · Spain (1) · Sweden (1)
Helen Heslop, MD (2) · Mark Minden, MD (2) · Nirali N Shah, M.D. (2) · Armin Ghobadi, M.D. (1) · Ashwin Gollerkeri, MD (1) · Beata Holkova, MD (1) · Carl June, MD (1) · Carlos A Ramos, MD (1) · Claudio Brunstein, MD, PhD (1) · Cynthia Wetmore, MD PhD (1) · David E Avigan, MD (1) · David Porter, MD (1) · Gary Jacob, Ph.D. (1) · Gary Jacob, PhD (1) · Guillermo Garcia-Manero, MD (1)
PMID 34515338, PMID 34687939, PMID 37486616, PMID 21993685, PMID 22009536, PMID 24777753, PMID 24782509, PMID 25682597, PMID 27400247, PMID 28054442, PMID 29144985, PMID 30668890, PMID 31699827, PMID 32023374, PMID 32286905, PMID 33666654, PMID 33822526, PMID 33869653, PMID 34156874, PMID 34309174, PMID 34889384, PMID 35126471, PMID 35435984, PMID 35605184, PMID 36402456, PMID 37295816, PMID 38170741, PMID 38238616, PMID 38376944, PMID 38473278, PMID 39576962, PMID 39908482, PMID 41411486, PMID 41671463, PMID 42248607
2018 (1), 2023 (1), K12CA167540 (1), RC2CA148431 (1)